These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 25704349)
1. Aldosterone blockade in CKD: emphasis on pharmacology. Schwenk MH; Hirsch JS; Bomback AS Adv Chronic Kidney Dis; 2015 Mar; 22(2):123-32. PubMed ID: 25704349 [TBL] [Abstract][Full Text] [Related]
2. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Buysse JM; Huang IZ; Pitt B Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443 [TBL] [Abstract][Full Text] [Related]
3. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Lazich I; Bakris GL Semin Nephrol; 2014 May; 34(3):333-9. PubMed ID: 25016403 [TBL] [Abstract][Full Text] [Related]
4. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812 [TBL] [Abstract][Full Text] [Related]
5. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698 [TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin-aldosterone system inhibitors in heart failure. Shearer F; Lang CC; Struthers AD Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393 [TBL] [Abstract][Full Text] [Related]
7. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria. Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114 [TBL] [Abstract][Full Text] [Related]
8. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria. Kim HY; Bae EH; Ma SK; Kim SW Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940 [TBL] [Abstract][Full Text] [Related]
9. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174 [TBL] [Abstract][Full Text] [Related]
10. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Weir MR; Rolfe M Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448 [TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Mavrakanas TA; Gariani K; Martin PY Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases. Weinberger MH; Luft FC Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130 [TBL] [Abstract][Full Text] [Related]
13. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819 [TBL] [Abstract][Full Text] [Related]
14. Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Lu Y; Ku E; Campese VM Curr Hypertens Rep; 2010 Aug; 12(4):303-6. PubMed ID: 20596805 [TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonist for renal protection. Ma TK; Szeto CC Ren Fail; 2012; 34(6):810-7. PubMed ID: 22463731 [TBL] [Abstract][Full Text] [Related]
16. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Remuzzi G; Perico N; Macia M; Ruggenenti P Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578 [TBL] [Abstract][Full Text] [Related]
17. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Khosla N; Kalaitzidis R; Bakris GL Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369 [TBL] [Abstract][Full Text] [Related]
18. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Márquez DF; Ruiz-Hurtado G; Ruilope LM; Segura J Expert Opin Pharmacother; 2015; 16(15):2283-92. PubMed ID: 26389772 [TBL] [Abstract][Full Text] [Related]
19. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Bianchi S; Bigazzi R; Campese VM Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956 [TBL] [Abstract][Full Text] [Related]
20. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. Ku E; Campese VM Pediatr Nephrol; 2009 Dec; 24(12):2301-7. PubMed ID: 19347366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]